Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open‐Label Study

Roxadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor developed to treat anemia in chronic kidney disease (CKD) patients. This Phase 3, randomized, open‐label, 24‐week study investigated the efficacy and safety of roxadustat in Japanese CKD patients with anemia on peritoneal di...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ther Apher Dial
Hlavní autoři: Akizawa, Tadao, Otsuka, Tetsuro, Reusch, Michael, Ueno, Mai
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons Australia, Ltd 2019
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7079122/
https://ncbi.nlm.nih.gov/pubmed/31222951
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1744-9987.12888
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky